Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were down 4% on Thursday . The company traded as low as $7.24 and last traded at $7.36, with a volume of 57,285 shares traded. The stock had previously closed at $7.67.

A number of analysts recently weighed in on KPTI shares. Canaccord Genuity restated a “buy” rating and set a $20.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, April 6th. Robert W. Baird started coverage on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. They issued an “outperform” rating and a $16.00 price target on the stock. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. Finally, Raymond James Financial Inc. started coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $19.50.

The firm’s market cap is $265.38 million. The stock has a 50-day moving average price of $7.42 and a 200 day moving average price of $7.79.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.01. Equities research analysts predict that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current year.

In related news, major shareholder Ltd Chione sold 18,824 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent quarter.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.